Reductions in mortality seen in association with ACE inhibitors, beta-blockers, thiazide diuretics
WEDNESDAY, Sept. 1, 2021 (HealthDay News) — Antihypertensive medication use is associated with a reduction in cancer-specific mortality among patients diagnosed with colorectal cancer (CRC), according to a study published in the August issue of Cancer Medicine.
Rajesh Balkrishnan, Ph.D., from the University of Virginia in Charlottesville, and colleagues conducted a noninterventional, retrospective analysis of 13,982 patients aged 65 years and older with CRC diagnosed from Jan. 1, 2007, to Dec. 31, 2012, in the Surveillance, Epidemiology, and End-Results Medicare database. The authors examined the association between antihypertensive drug utilization and the American Joint Committee on Cancer stage I to III CRC mortality rates.
The researchers found that the use of antihypertensive drugs was associated with decreased cancer-specific mortality among patients diagnosed with CRC (hazard ratio, 0.79). Angiotensin-converting enzyme inhibitors, beta-blockers, and thiazide diuretics were associated with decreased mortality (hazard ratios, 0.84, 0.83, and 0.83, respectively). There was also an association between adherence to antihypertensive therapy and reduced cancer-specific mortality (hazard ratio, 0.94).
“The results of this study are novel and suggest future research analyzing the application of antihypertensives as a tool to improve cancer-related mortality,” the authors write.
Updated Recommendations Address Medications to Prevent Migraine in Adults
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis
Achieving Low Serum Urate Levels Can Cut Risk for Cardiovascular Events in Gout